<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902186</url>
  </required_header>
  <id_info>
    <org_study_id>RALBAT</org_study_id>
    <nct_id>NCT01902186</nct_id>
  </id_info>
  <brief_title>Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir</brief_title>
  <acronym>RALBAT</acronym>
  <official_title>Switching HIV-positive Women on Tenofovir/Emtricitabine Plus Boosted Atazanavir to RALtegravir Plus Boosted ATazanavir: A Pilot Randomized Clinical Trial Investigating 48-weeks Changes in Bone Mineral Density</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Giovanni Di Perri</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Turin, Italy</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the high prevalence of bone alteration in the course of HIV infection or antiretroviral&#xD;
      treatment and the favourable properties of raltegravir the investigators designed this pilot&#xD;
      randomized and controlled study. Adult female HIV-positive patients on successful treatment&#xD;
      with tenofovir/emtricitabine plus atazanavir plus ritonavir will be randomized either to&#xD;
      continue such a regimen or to switch to raltegravir plus atazanavir plus ritonavir. Bone&#xD;
      mineral density changes will be compared in the two groups at 48 weeks: the hypothesis is&#xD;
      that removing tenofovir and using tenofovir will increase bone mineral density at 48 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to assess the improvement in Bone Mineral Density and markers of bone&#xD;
      turnover in women on TDF/FTC (tenofovir disoproxil fumarate/ emtricitabine)+ ATV/r&#xD;
      (atazanavir/ritonavir) in a switch arm (RAL (raltegravir) + ATV/r) vs. an unchanged arm&#xD;
      (TDF/FTC + ATV/r).&#xD;
&#xD;
      The clinical hypothesis is that removing tenofovir (associated to a boosted PI, and therefore&#xD;
      in the worst clinical scenario) in both pre-menopausal and menopausal women could be&#xD;
      beneficial and being associated with reduced bone mineral density loss measured by DEXA&#xD;
      (densitometry)scan scores and markers of bone turnover. The underlying mechanism is believed&#xD;
      to be the reduction in hyper-phosphaturia induced by proximal tubular dysfunction: therefore&#xD;
      measuring renal tubular markers and hormones involved in calcium and phosphorus homeostasis&#xD;
      (such as vitamin D and parathormone) will explain the suspected mechanism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment&#xD;
  </why_stopped>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variations from baseline in DEXA-measured bone mineral density (t-score, spine and femur)</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>variations from baseline in CTX (C-terminal telopeptide of type I collagen) and OC (Osteocalcin)</measure>
    <time_frame>24 and 48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the variation in renal function</measure>
    <time_frame>48 weeks</time_frame>
    <description>glomerular filtration rate, urinary markers of tubular dysfunction (nondiabetic glucosuria, altered resorption of phosphorus, hyperaminoaciduria, b2-micro-globuline excretion and abnormal uric acid excretion.) and urinary retinol binding protein</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cholesterol changes at 48 weeks in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Cholesterol levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Triglycerides changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Tryglicerdies levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucose Fasting Levels changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Glucose Fasting Levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Insulin levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Parathyroid hormone changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Parathyroid hormone levels in the two arms</description>
  </other_outcome>
  <other_outcome>
    <measure>Vitamine D (25-OH-Vitamine D) changes in the two arms</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in Vitamine D (25-OH-Vitamine D)levels in the two arms</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>HIV Infection</condition>
  <condition>Osteopenia</condition>
  <arm_group>
    <arm_group_label>raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>raltegravir and atazanavir and ritonavir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>tenofovir/emtricitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tenofovir/emtricitabine and atazanavir and ritonavir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir and atazanavir and ritonavir</intervention_name>
    <description>switch tenofovir/emtricitabine to raltegravir</description>
    <arm_group_label>raltegravir</arm_group_label>
    <other_name>Isentress (raltegravir)</other_name>
    <other_name>Reyataz (atazanavir)</other_name>
    <other_name>Norvir (ritonavir)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir/emtricitabine and atazanavir and ritonavir</intervention_name>
    <description>no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)</description>
    <arm_group_label>tenofovir/emtricitabine</arm_group_label>
    <other_name>tenofovir/emtricitabine (Truvada)</other_name>
    <other_name>atazanavir (Reyataz)</other_name>
    <other_name>ritonavir (norvir)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult HIV-positive female patients;&#xD;
&#xD;
          -  osteopenia (t-score from -1 to -2.5);&#xD;
&#xD;
          -  On antiretroviral treatment with tenofovir/emtricitabine and atazanavir/ritonavir&#xD;
             (300/100 mg) for at least six months;&#xD;
&#xD;
          -  Plasma HIV RNA below 50 copies/ml since six months;&#xD;
&#xD;
          -  Premenopausal women: female patients at any phase of the reproductive period with&#xD;
             regular menstrual cycles and normal FSH (&lt; 25 ng/mL) That would probably exclude&#xD;
             patients with ovarian or endocrinological dysfunctions. Pre and postmenopausal should&#xD;
             be therefore well-characterized.&#xD;
&#xD;
          -  Women in menopausal period (the menopause was defined as 12 months of amenorrhoea&#xD;
             without any pathological or physiological cause and using the endocrinological&#xD;
             definition of ovary insufficiency (LH (Luteic hormone) &gt;25ng/mL, FSH (follicule&#xD;
             stimulating hormone)&gt;25ng/mL and E2 (Estradiol)&lt;30ng/mL).&#xD;
&#xD;
          -  Each premenopausal sexually active subject of child-bearing potential must agree to&#xD;
             use a medically accepted method of contraception while receiving protocol-specified&#xD;
             medication and for 3 months after stopping the medication.Medically accepted methods&#xD;
             of contraception include condoms (male or female) with or without a spermicidal agent,&#xD;
             diaphragm or cervical cap with spermicide, medically prescribed IUD (intrauterine&#xD;
             device), inert or copper-containing IUD, hormone-releasing IUD, systemic hormonal&#xD;
             contraceptive, and surgical sterilization (eg, hysterectomy or tubal ligation).&#xD;
&#xD;
          -  Postmenopausal women are not required to use contraception.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or current evidence of any condition, therapy, laboratory abnormality or other&#xD;
             circumstance that might confound the results of the study, or interfere with the&#xD;
             patient's participation for the full duration of the study, such that it is not in the&#xD;
             best interest of the patient to participate.&#xD;
&#xD;
          -  Documented resistance to Raltegravir or/and Atazanavir.&#xD;
&#xD;
          -  Patient with significant hypersensitivity or other contraindication to any of the&#xD;
             components of the study drugs.&#xD;
&#xD;
          -  Patient has a current (active) diagnosis of acute hepatitis due to any cause&#xD;
&#xD;
          -  Patient with coinfection HIV/HBV (Human Hepatitis virus B)&#xD;
&#xD;
          -  Liver cirrhosis&#xD;
&#xD;
          -  Osteoporosis (t-score less than 2.5).&#xD;
&#xD;
          -  Secondary endocrinological cause of low BMD (Bone mineral density)&#xD;
&#xD;
          -  Chronic steroid intake;&#xD;
&#xD;
          -  Chronic kidney disease (estimated glomerular filtration rate below 60 ml/min);&#xD;
&#xD;
          -  Concomitant use of bisphosphonate.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Di Perri, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Turin, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Torino</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>July 10, 2013</study_first_submitted>
  <study_first_submitted_qc>July 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <last_update_submitted>October 14, 2018</last_update_submitted>
  <last_update_submitted_qc>October 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Turin, Italy</investigator_affiliation>
    <investigator_full_name>Giovanni Di Perri</investigator_full_name>
    <investigator_title>Full professor of Infectious Diseases</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>osteopenia</keyword>
  <keyword>t-score</keyword>
  <keyword>DEXA</keyword>
  <keyword>tenofovir</keyword>
  <keyword>raltegravir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

